Application of baicalin in treatment of sarcopenia
By activating the wnt/β-catenin pathway, baicalin inhibits inflammation and promotes the differentiation of muscle satellite cells, solving the gap in the existing technology of sarcopenia treatment, significantly improving muscle mass and function, and providing effective treatment methods for sarcopenia. .
Patent Information
- Application Number
- CN202410939810.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-08
AI Technical Summary
There is currently no effective drug or intervention method that can prevent, delay or reverse the progress of sarcopenia. The effects of existing exercise training and nutrition interventions are uncertain and there is a lack of large sample, long-term prospective clinical studies.
By activating the wnt/β-catenin pathway, baicalin inhibits inflammation, promotes the proliferation and differentiation of muscle satellite cells, and improves muscle mass and function, which is used to treat sarcopenia.
Baicalin significantly reduces the inflammation indicators in mice, increases muscle mass and function, promotes the increase of type IIa muscle fibers in muscle tissue, and improves muscle function, providing an effective treatment method for sarcopenia.
Smart Images

Figure CN118903171A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to the application of baicalin in treating sarcopenia. Background Art
[0002] Sarcopenia is an aging-related syndrome characterized by a progressive decrease in skeletal muscle mass and strength. It is an important cause of functional impairment, decreased quality of life, and even death in the elderly. Currently, there is no definite intervention method and no drug that can prevent, delay, or reverse the progression of sarcopenia.
[0003] At present, the intervention methods for sarcopenia mainly include exercise training combined with nutritional support therapy, and resistance training is the best exercise training. However, the high-risk population for sarcopenia is the elderly, who often suffer from various underlying diseases and find resistance training difficult to implement. Nutritional intervention for sarcopenia mainly includes supplementation of protein, essential amino acids (EAA), β-hydroxyβ-methylbutyrate (HMB), fatty acids, etc. The supplementation of these nutrients can provide a basis for protein synthesis and muscle reconstruction. However, the conclusions of nutritional intervention on the increase of muscle mass and muscle strength are inconsistent in different studies, and there is a lack of large-sample, long-term clinical prospective studies.
[0004] In summary, although exercise intervention and nutritional supplements are currently important rehabilitation treatment strategies for sarcopenia, effective strategies widely recognized by the clinic need to be discovered and verified. It is urgent to explore more effective intervention methods that can prevent, delay or block the progression of sarcopenia, which has great practical significance and social value. Summary of the invention
[0005] The purpose of the present invention is to provide the use of baicalin in the treatment of sarcopenia to solve the above technical problems.
[0006] The technical solution provided by the present invention is: application of baicalin in treating sarcopenia.
[0007] In a specific embodiment of the present invention, baicalin can inhibit inflammation and improve muscle quality and muscle function by activating the wnt / β-catenin pathway.
[0008] A second object of the present invention is to provide a medicine or composition with baicalin as an active ingredient, wherein the medicine or composition is used to treat sarcopenia.
[0009] In a specific embodiment of the present invention, the drug or composition is used to activate the wnt / β-catenin pathway.
[0010] In a specific embodiment of the present invention, the drug or composition is used to promote the proliferation and differentiation of muscle satellite cells.
[0011] In a specific embodiment of the present invention, the medicine or composition is used to improve forelimb grip strength.
[0012] In a specific embodiment of the present invention, the drug or composition is used to inhibit the inflammatory response of sarcopenia.
[0013] The present invention proves through in vitro experiments that after intervention with baicalin, the inflammatory indicators in mice are reduced (IL-1, TNF-α), and the formation of C2C12 cell myotubes is increased. The expression levels of β-catenin mRNA and protein are increased, and the downstream genes of β-catenin c-myc, CD44, cyclin D1 and Oct4 are activated. In vivo experiments have shown that after intervention with baicalin, the grip strength and muscle mass of mice increase, the number of type IIa muscle fibers in muscle tissue increases, the expression levels of β-catenin mRNA and protein increase, and the downstream genes of β-catenin c-myc, CD44, cyclin D1 and Oct4 are activated. That is. The baicalin provided by the present invention can inhibit inflammation by activating the wnt / β-catenin pathway, improve muscle mass and muscle function, and can provide an effective treatment approach for sarcopenia. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The results are for the expression levels of IL-6 and TNF-α in mouse serum.
[0015] Figure 2 Shown are the results of myotube formation of C2C12 cells in each group.
[0016] Figure 3 The expression results of β-catenin RNA and protein in each group; in the figure, the left figure is the expression of β-catenin RNA; the right figure is the expression of protein (right figure).
[0017] Figure 4 The expression results of β-catenin downstream genes in each group.
[0018] Figure 5 The results of HE and MHC staining of mouse skeletal muscle; in the figure, A: HE staining of skeletal muscle of mice in the control group; B: HE staining of skeletal muscle of mice in the intervention group; C: corresponding MHC staining of mice in the control group; D: corresponding MHC staining of mice in the intervention group.
[0019] Figure 6 These are the grip strength results of mice in the control group and the intervention group.
[0020] Figure 7 OD values of mice in each group tested on the 1st, 3rd, 5th and 7th days. DETAILED DESCRIPTION
[0021] The following is further described in detail through specific implementation methods:
[0022] All quantitative data in the present invention are expressed as mean ± standard deviation (SD). SPSS (SPSS19.0) was used to analyze the differences between the groups by student t. P < 0.05 was considered statistically significant.
[0023] 1. Experimental Grouping
[0024] The experiment was divided into a control group and an intervention group.
[0025] In the in vivo experiment, the intervention group: SAMP8 accelerated aging mice (Hua Fu Kang Biotechnology Company, 13009A) were given 40 mg / kg of baicalin by gavage every day. The control group: SAMP8 accelerated aging mice were given physiological saline by gavage every day.
[0026] In the in vitro experiment, the intervention group: SAMP8 accelerated aging mice were given 50mmol / L baicalin solution added to the culture medium every day by gavage to intervene in C2C12 cells (mouse myoblasts, Pronocell, CL-0044). The baicalin solution was prepared by dissolving in bovine serum albumin (BSA). The control group used the same dose of BSA added to the culture medium to intervene in C2C12 cells.
[0027] 2.ELISA analysis
[0028] SAMP8 accelerated aging mice were used as an animal model of sarcopenia. The mice began to show sarcopenia from August, and 10 months of age was used as the endpoint of this experiment. The experimental endpoint was set at 10 months of age. The mice were euthanized at 10 months of age, and whole blood and gastrocnemius muscle of the mice were collected. After the whole blood was allowed to stand, the upper serum was collected and the next experiment was carried out. The gastrocnemius muscle of the mice was frozen and sectioned and used in subsequent experiments.
[0029] In this experiment, ELISA kits (Abcam, ab222503 / ab208348) were used to analyze IL-6 and TNF-α in the serum of SAMP8 accelerated aging mice. ELISA assays were performed according to the instructions. Washing buffer, calibrator diluent RD5-26, substrate solution, and mouse IL-6 / TNF-α, standards were prepared according to the instructions. The control was also reconstituted with 1.0 ml of double distilled water. 50 ul of assay diluent RD1W was added to each well, and then 50 μl of standard, sample or control was added to the corresponding well. The plate was incubated at room temperature for 3 hours, washed 4 times with washing buffer, and 100 μl of substrate solution was added and incubated at room temperature for 30 min. 100 μl of stop solution was added to stop the color reaction. The absorbance of each well at a wavelength of 570 nm was measured using a spectrophotometer (BioTek) to calculate the IL-6 / TNF-α concentration.
[0030] The ELISA method was used to detect the IL-6 and TNF-α levels in the control group and the intervention group. Figure 1 As shown in the figure, the levels of serum inflammatory indicators (IL-6, TNF-α) in the intervention group were significantly lower than those in the control group (p < 0.05).
[0031] 3. Myotube formation
[0032] Sodium palmitate (50 mM) was used to induce inflammation in C2C12 cells. After 48 hours of induction, 2% horse serum was used to induce myogenesis in both groups of C2C12 cells. After 5 days of induction, the cells were immunofluorescently stained (MHC IIa) to observe the formation of myotubes. Figure 2 As shown in the figure, the number of myotubes formed in the intervention group was significantly increased compared with that in the control group.
[0033] 4. Western Blotting and Quantitative Real-time PCR
[0034] 20 μg of protein extracted from mouse muscle tissue was mixed with 5× loading buffer (Biotech), the mixture was boiled at 100°C for 5 min, and SDS-PAGE gel electrophoresis was performed to separate the protein. 5× protein loading buffer (SDS-PAGE Sample Loading Buffer, 5X) is a modified 5-fold concentrated protein loading buffer with bromophenol blue as the dye, commonly used for loading SDS-PAGE protein samples.
[0035] Prepare SDS-PAGE gel: 4 ml of 14% SDS-PACE decomposition gel is cast into the assembled gel box for gel polymerization, then, 1 ml of 4% SDS stacking gel is added, and 10 tooth combs are fixed to the box to form holes for sample loading. Before sample loading, the stacking gel is balanced with running buffer. Protein samples (extracted from mouse muscle tissue) and standard proteins (1 mg / ml) are loaded into the holes of the gel, and the gel is electrophoresed at 120V for 2 hours at room temperature. Afterwards, the gel is removed and transferred with transfer buffer (transfer buffer, GenScript) for protein transfer.
[0036] The PVDF membrane was activated with 100% methanol, and the gel and PVDF membrane were placed in a protein blotting box and filled with transfer buffer. The proteins in the gel were transferred to the membrane on ice at 100V for about 60min. After transfer, the PVDF membrane was blocked with 5% skim milk for 1 hour and then incubated overnight at 4°C with the primary antibody, anti-β-catenin (1:3000, BD Biosciences). After washing 3 times with Tris-buffered saline containing Tween-20 (TBST), the membrane was further incubated with a secondary antibody (anti-rabbit, Santa Curz) conjugated with horseradish peroxidase (HRP) at room temperature for 2 hours, and then the membrane was washed with TBST for 10min5 times. The blot was detected and photographed using a scanner.
[0037] Quantitative real-time PCR was performed using Power SYBR Green PCR Master Mix (Thermo). The reaction mixture contained 5 μl Power SYBR Green PCR Master Mix, 0.25 μl forward primer, 0.25 μl reverse primer, 2 μl cDNA template, and 2.5 μl enzyme-free water, for a total of 10 μl. After thorough mixing, the reaction mixture was transferred to a 96-well plate (Thermo) using a pipette. The 96-well plate was centrifuged at 3000 rpm for 3 min to ensure that all the solution was transferred to the bottom of the well, and then the 96-well plate was loaded into the StepOnePlus Real-Time PCR System (Applied Biosystem). The reaction program was as follows: PCR reaction started at 98 °C, the denaturation step lasted for 10 min, followed by 45 cycles at 98 °C for 5 s, and reaction at 60 °C for 1 min. After the reaction was completed, the PCR products were analyzed by melting curve analysis to determine the specificity of the specific primer pair. β-catenin, a key gene in the Wnt / β-catenin signaling pathway, and its downstream genes C-myc, CD44, cyclinD1, and Oct4 were analyzed.
[0038] β-catenin: It binds to proteins such as E-cadherin, a-catenin, Axin / APC degradation complex, and T cell factor (TCF) / Lymphoid enhancer factor-1 (LEF-1) transcription factor through its middle region, exerting its functions of cell adhesion and transducing intercellular signals. β-catenin is a key gene in the Wnt / β-catenin signaling pathway, which is closely related to inflammatory response. C-myc, CD44, cyclinD1, and Oct4 are downstream genes of β-catenin, and the activation of these genes also indicates the activation of the Wnt / β-catenin pathway.
[0039] The primers used in the experiment are listed in Table 1 below.
[0040] Table 1: Mouse qPCR primers (F: forward, R: reverse)
[0041]
[0042]
[0043] Experimental results:
[0044] qPCR and Western Blot (WB) were used to detect the mRNA expression and protein level expression of β-catenin in the muscle tissue of the control group and the intervention group of mice. Figure 3 As shown, both RNA and protein levels were significantly increased in the intervention group, suggesting that the pathway was activated.
[0045] PCR was used to detect the expression of β-catenin downstream genes. The experimental results were as follows Figure 4 As shown, the expression of c-myc, CD44, cyclinD1, and oct4 mRNA all showed an upward trend, and the increase of cyclinD1 and oct4 mRNA expression was significantly different (p < 0.05), indicating that the wnt / β-catenin pathway was activated.
[0046] 5. HE staining and MHC staining of mouse muscle cross sections
[0047] Immunofluorescence staining of cells:
[0048] Immunofluorescence staining was used to stain and analyze the C2C12 cells after differentiation. MHC IIa (SC-71) (DSHB) was used as the primary antibody and Alexa Fluor 488IgG1 (Invitrogen) was used as the secondary antibody. The cells were fixed with 4% paraformaldehyde for 15 minutes, washed three times with PBS, blocked with 4% BSA (Sigma) and incubated for 1 hour, then the primary antibody was added and incubated overnight at 4°C. The next day, the cells were washed three times with PBS, the secondary antibody was added, and the cells were incubated at room temperature for 1 hour. After washing three times with PBS, the sealing medium (Biyuntian) with DAPI was used to cover the sealing medium. The cells were photographed using a fluorescence microscope (Olympus).
[0049] Tissue immunofluorescence staining:
[0050] MHCI (BA-F8), MHC IIa (SC-71) and MHC IIb (BF-F3) primary antibodies (DSHB) were mixed together to form an antibody mixture. Secondary antibodies of Alexa Fluor 350IgG2b, Alexa Fluor 488IgG1 and Alexa Fluor 555IgM (Invitrogen) were mixed to form a secondary antibody mixture. The concentration of the primary antibody mixture and the secondary antibody mixture was 4μg / ml. The frozen sections stored in a -20°C refrigerator were placed at room temperature and air-dried, and 4% bovine serum albumin (BSA, Sigma) was added to the slides for blocking and incubation for 1 hour, and then the primary antibody mixture was added, and the sections were incubated with the primary antibodies at 4°C overnight. The next day, after washing three times with PBS, the secondary antibody mixture was added to the slides and incubated at room temperature for 1 hour. After washing 3 times with PBS, it was covered with a mounting medium (Invitrogen). Images of the entire cross-section of each muscle sample were taken by fluorescence microscopy. The images were automatically merged together by the software. Merged images were analyzed by Image J software (NIH). For myofiber typing, the three types of fibers (type I, type IIa, type IIb) were analyzed throughout the cross section of each muscle sample, and images were quantified to assess the percentage of the three types of fibers in each muscle sample.
[0051] The experimental results are as follows Figure 5 As shown: HE staining and MHC staining were used to stain the cross-sectional sections of mouse skeletal muscle. HE staining found that SAMP8 accelerated the increase in the number of central nuclear muscle fibers in the gastrocnemius muscle of aging mice, indicating that baicalin promoted the differentiation of muscle satellite cells. MHC staining results showed that the number of IIa muscle fibers in the intervention group increased, indicating an increase in fast muscle fibers A. The above results preliminarily confirmed that baicalin promoted the proliferation and differentiation of muscle satellite cells.
[0052] 6. Mouse Grip Strength Test
[0053] The grip strength of mice was measured using a dynamometer. The mouse's tail was held, and then the mouse's front paws were grasped onto a wire mesh connected to the dynamometer, and the mouse's tail was slowly pulled until the mouse removed its front paws from the mesh. The peak value of each measurement was recorded. The measurement was repeated three times for each mouse, and the average value of the force was taken. In the present invention, the data measured was forelimb grip strength.
[0054] The experimental results are as follows Figure 6 As shown: There was a statistically significant difference in the increase in grip strength between the two groups. The grip strength of the mice in the intervention group was significantly higher than that in the control group, indicating that baicalin improved the muscle function of mice.
[0055] In summary, in vitro experiments have shown that after baicalin intervention, the inflammatory indicators in mice (IL-1, TNF-α) were reduced, and the formation of C2C12 cell myotubes increased. The expression levels of β-catenin mRNA and protein increased, and the downstream genes of β-catenin c-myc, CD44, cyclin D1 and Oct4 were activated. In vivo experiments have shown that after baicalin intervention, the grip strength and muscle mass of mice increased, the number of type IIa muscle fibers in muscle tissue increased, the expression levels of β-catenin mRNA and protein increased, and the downstream genes of β-catenin c-myc, CD44, cyclin D1 and Oct4 were activated. All of the above indicators were statistically significant. This shows that baicalin can inhibit the inflammatory response of sarcopenic mice and improve the muscle mass and muscle function of sarcopenic mice.
[0056] 7.CCK-8 Experiment
[0057] The experiment was divided into 4 groups, namely, the cell control group, the 30μM intervention group, the 60μM intervention group, and the 120μM intervention group. Specifically, the cell control group used ordinary low-glucose DMEM culture medium, and the intervention group was prepared by dissolving different volumes of drugs in low-glucose DMEM culture medium according to the required concentration. 2000 cells were added to each well of the 96-well plate. According to the experimental design, different intervention factors of the culture medium were added to each group, and 200ml was added to each well. CCK8 detection was performed at each detection time point; 20μCCK-8 solution was added to each well. The wells with the corresponding amount of cell culture fluid and CCK-8 solution but no cells were added were used as blank controls; incubation continued in the cell culture incubator for 1 hour. Then the absorbance was measured at a wavelength of 450nm using an ELISA reader, recorded and analyzed.
[0058] Through CCK-8 experiment, different concentrations of baicalin were used for intervention. The OD of myoblasts of mice in each group one day after intervention showed that 30 and 60 μM concentrations of baicalin had less toxicity. Figure 7 As shown, the OD values of mice in each group were detected on the 3rd, 5th and 7th days, which showed that the number of mouse myoblasts was higher under the intervention of 60 μM concentration of baicalin, indicating that this concentration can significantly promote the proliferation of myoblasts.
[0059] The preferred specific embodiments of the present invention are described in detail above. It should be understood that a person skilled in the art can make many modifications and changes based on the concept of the present invention without creative work. Therefore, any technical solution that can be obtained by a person skilled in the art through logical analysis, reasoning or limited experiments based on the concept of the present invention on the basis of the prior art should be within the scope of protection determined by the claims.
Claims
1. Application of baicalin in the preparation of drugs for treating sarcopenia.
2. The use according to claim 1, It is characterized in that The baicalin can inhibit inflammation and improve muscle mass and muscle function by activating the wnt / β-catenin pathway.
3. A medicine or composition with baicalin as an active ingredient, It is characterized in that The medicine or composition is used for treating sarcopenia.
4. The medicine or composition with baicalin as an active ingredient according to claim 3, It is characterized in that The drug or composition is used to activate the wnt / β-catenin pathway.
5. The medicine or composition with baicalin as an active ingredient according to claim 3, It is characterized in that The medicine or composition is used for promoting the proliferation and differentiation of muscle satellite cells.
6. The medicine or composition with baicalin as an active ingredient according to claim 3, It is characterized in that The medicine or composition is used for improving the grip strength of animal forelimbs.
7. The medicine or composition comprising baicalin as an active ingredient according to claim 3, It is characterized in that The medicine or composition is used to inhibit the inflammatory response of sarcopenia.
